TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04644432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (A specification is listed under each arm)
Description: Study drugs and dosages are listed in the description of arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (A specification is listed under each arm)
Description: Study drugs and dosages are listed in the description of arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (A specification is listed under each arm)
Description: Study drugs and dosages are listed in the description of arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (A specification is listed under each arm)
Description: Study drugs and dosages are listed in the description of arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measurement
Description: PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measurement
Description: PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measurement
Description: PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measurement
Description: PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
Study: NCT02702830

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET
Study: NCT00328042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Workshop
Description: The workshop is a once per week 2.5 hour group that meets for six weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: This is an individual self-paced at home study program.
Study: NCT03552354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban plus dual antiplatelet
Description: A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
Study: NCT02702830

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03416205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbao electric knife
Description: Erbao electric knife is used to cut the Duodenal sphincter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbao electric knife
Description: Erbao electric knife is used to cut the Duodenal sphincter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-cavity incision knife
Description: Three-cavity incision knife is used to cut the Duodenal sphincter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-cavity incision knife
Description: Three-cavity incision knife is used to cut the Duodenal sphincter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Columnar expansion balloon
Description: Columnar expansion balloon is used to expand the the Duodenal sphincter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Columnar expansion balloon
Description: Columnar expansion balloon is used to expand the the Duodenal sphincter
Study: NCT03823365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab Expanded T-cells (BET)
Description: Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109
Study: NCT00350519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive standard of care based on the Institution's treatment policy.
Study: NCT02358954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Measurement of warm and cold detection and pain thresholds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHEPS
Description: Measurement of amplitude and latency of cortically evoked potentials

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Turntable

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vection stimulation
Study: NCT00659854

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non milk or soy based formula
Description: Babies will be given a non milk or soy base formula for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk based formula
Description: Babies will be given a milk based formula for 12 weeks
Study: NCT03670537

Intervention type: DIAGNOSTIC_TEST
Intervention: Iron parameters
Description: Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
Study: NCT00651547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study: NCT04862104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
Study: NCT00158327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based collaborative care
Description: Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
Study: NCT01108653

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care sick-leave management
Description: Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Structuralised sick-leave program
Description: Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
Study: NCT04051372

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopic Alveolar Lavage
Description: The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS
Study: NCT02270606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo total mesorectal excision
Study: NCT04163302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-PD1-CART Cell
Description: This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Study: NCT03079284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holding during cooling
Description: An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
Study: NCT03572998

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green (ICG)
Description: Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
Study: NCT00591487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
Study: NCT01899846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate 250 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate 250 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate 250 mg/ml
Study: NCT00288587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV loop diuretic
Description: Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NxStage System One
Description: Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
Study: NCT04000828

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of Sensimed Triggerfish
Description: Sensimed Triggerfish is placed on the corneal surface
Study: NCT04162392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shared decision making
Description: Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
Study: NCT03351218

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral testing - computerized tasks
Description: Cognitive behavioral testing and cerebral MRI
Study: NCT00875836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Flexible dose, up to 60 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flexible dose, up to 60 mg daily
Study: NCT00002484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00823459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Archival Tissue Analysis
Description: Correlative studies
Study: NCT04226924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trehalose
Description: 90 mg/ml trehalose solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: 90 mg/ml trehalose solution for IV infusion
Study: NCT05472428

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear cells
Study: NCT05126797

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: OTHER
Intervention: Stent Device
Description: Wear customized 3D printed oral stent
Study: NCT05465889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol Electrolyte
Description: Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
Study: NCT04305925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Laser Ablation
Description: Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
Study: NCT00856050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Taken orally once a day continuously
Study: NCT05246423

Intervention type: DIAGNOSTIC_TEST
Intervention: Observation group
Description: Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
Study: NCT03910127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anlotinib
Description: matching placebo
Study: NCT01657422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE+
Description: Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
Study: NCT01253434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type A patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type B patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type C patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type D patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type E patch
Study: NCT00690521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Furosemide + Hydrochlorothiazide
Description: A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Furosemide + Metolazone
Description: A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
Study: NCT03225092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet rich plasma injection
Description: Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
Study: NCT00972114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG combined cardiomyoplasty
Description: coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined pedicled omentum graft
Description: Coronary artery bypass graft surgery combined pedicled omentum graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG alone
Description: Coronary artery bypass graft surgery alone
Study: NCT02658032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized cessation care
Description: Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: personalized cessation care
Description: Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bio feedback
Description: Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: bio feedback
Description: Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.

Intervention type: OTHER
Group type: OTHER
Intervention: standard care

Intervention type: OTHER
Group type: OTHER
Intervention: standard care

Intervention type: OTHER
Group type: OTHER
Intervention: standard care